Immunoglobulins (Ig): Structural Basis, Functional Mechanisms, and Practical Considerations—A Technical Review

Immunoglobulins are the central effector molecules of adaptive humoral immunity. They are produced by B cells and their terminally differentiated plasma cells and contribute to pathogen clearance, maintenance of immune homeostasis, and the development of immunopathology through a dual architecture: highly specific antigen recognition mediated by variable regions and multi-pathway effector amplification mediated by constant regions. Their molecular diversity arises from layered mechanisms including V(D)J gene rearrangement, somatic hypermutation, and class-switch recombination. Structurally, immunoglobulins rely on a modular Fab/Fc framework and Fc glycosylation to fine-tune affinity, half-life, and effector modalities. On this biological foundation, plasma-derived immunoglobulin preparations and recombinant engineered antibodies together constitute key technology platforms for modern passive immunotherapy, immunomodulatory therapy, and antibody drug development.

Keywords: immunoglobulin; antibody; Fab/Fc; V(D)J rearrangement; somatic hypermutation; class-switch recombination; Fc receptor; complement; FcRn; IVIG; monoclonal antibody

I. Overview

1.1 Definition of Immunoglobulins

Immunoglobulins (Igs) are a class of glycoproteins synthesized and secreted by B cells and their terminally differentiated plasma cells and represent the core effector molecules of humoral immune responses. Secreted immunoglobulins in blood and body fluids specifically recognize and neutralize pathogens, toxins, and abnormal cells. In parallel, membrane-bound immunoglobulins serve as the antigen-recognition component of the B cell receptor (BCR) complex, participating in antigen sensing and signal transduction, thereby enabling adaptive B cell responses to external antigens.

1.2 Relationship Between “Antibodies” and Immunoglobulins

“Antibody” emphasizes the functional property of antigen-specific binding and immune effector activity, whereas “immunoglobulin” refers more to structural and family classification. In most contexts, the two terms can be regarded as synonymous: serum-detectable IgG, IgA, IgM, and related molecules are both immunoglobulins and functional antibodies. Based on heavy-chain constant region types, human immunoglobulins are categorized into five isotypes: IgG, IgA, IgM, IgD, and IgE. IgG is further divided into IgG1–IgG4, and IgA into IgA1 and IgA2. Distinct isotypes and subclasses show marked differences in tissue distribution, half-life, and effector functions.

II. Molecular Structural Basis: From the H₂L₂ Scaffold to Fab/Fc Specialization

2.1 The Canonical H₂L₂ “Y-shaped” Architecture

(1) Overall scaffold and basic units

A typical immunoglobulin consists of two heavy (H) chains and two light (L) chains. Disulfide bonds and noncovalent interactions stabilize the four chains into a Y-shaped H₂L₂ structure. Each chain contains an N-terminal variable (V) region and a C-terminal constant (C) region. The heavy-chain constant region typically comprises multiple domains (e.g., CH1, CH2, CH3), whereas the light-chain constant region contains a single CL domain.

(2) Functional division of labor between Fab and Fc

The Fab (fragment antigen-binding) region is formed by VH/VL together with adjacent CH1/CL domains and constitutes the antigen recognition module. The Fc (fragment crystallizable) region is formed by heavy-chain constant domains and provides the interaction interface for Fc receptors, complement component C1q, neonatal Fc receptor (FcRn), and other effector molecules. The hinge region connects Fab and Fc and imparts conformational flexibility to Fab, influencing antigen accessibility, oligomerization tendency, and protease sensitivity, thereby indirectly modulating effector output.

2.2 Variable Regions, CDRs, and the “Fine Specificity” of Antigen Binding

Within variable regions, relatively conserved framework regions (FRs) and highly variable complementarity-determining regions (CDR1–3) can be distinguished. Six CDRs (three on VH and three on VL) form the antigen-binding site (paratope) in three-dimensional space and determine affinity and specificity toward a given epitope. Among these, heavy-chain CDR3 typically exhibits the greatest sequence and conformational diversity and often contributes most to recognition. For a given antibody, it is important to distinguish:

① Affinity: the binding strength between a single binding site and an epitope;

② Avidity: the effective overall binding strength in multivalent interactions, which is particularly prominent for polymeric isotypes such as pentameric IgM.

2.3 Fc Glycosylation as a Regulator of Effector Functions

Using IgG as a representative example, the CH2 domain within the Fc region contains a conserved N-glycosylation site. Glycan composition and conformation (e.g., fucosylation, galactosylation, sialylation) can substantially influence:

① binding affinity to different Fcγ receptors and the magnitude of cellular effector functions such as ADCC/ADCP;

② recruitment of complement component C1q and activation efficiency of the classical pathway;

③ the overall pro-inflammatory versus anti-inflammatory functional bias.

Accordingly, Fc glycosylation is often considered a “second layer of encoding” for effector function and represents a critical variable in therapeutic antibody design and quality control.

III. Molecular Basis of Antibody Diversity

3.1 V(D)J Rearrangement and Junctional Diversity

During early B cell development in the bone marrow, immunoglobulin variable region genes undergo V(D)J rearrangement to generate the foundational receptor repertoire: heavy-chain variable regions are formed by recombination of V, D, and J segments, whereas light-chain variable regions are formed by recombination of V and J segments. Recombination-activating enzymes such as RAG1/2 recognize recombination signal sequences (RSS) and execute cleavage and rejoining within defined spatiotemporal windows. During joining, small imprecisions at cleavage sites and terminal deoxynucleotidyl transferase (TdT)-mediated N-nucleotide addition together generate junctional diversity, producing a theoretical receptor repertoire far exceeding that derived from combinatorial diversity alone.

3.2 Somatic Hypermutation and Affinity Maturation

Following antigen stimulation, activated B cells undergo somatic hypermutation (SHM) and selection within germinal centers of secondary lymphoid organs. Activation-induced cytidine deaminase (AID) induces C→U deamination within V-region coding sequences; subsequent mismatch repair pathways introduce point mutations. Under selective pressure imposed by antigen binding and T helper cell signals, high-affinity clones survive and expand, whereas low-affinity or autoreactive clones are eliminated, resulting in affinity maturation and optimization of specificity.

3.3 Class-Switch Recombination and “Effector Interface Switching”

Class-switch recombination (CSR) changes the heavy-chain constant region (e.g., switching from μ to γ, α, or ε) without altering the V region or antigen specificity, enabling switching from IgM/IgD to IgG, IgA, or IgE. CSR also depends on AID-mediated DNA breaks and recombination. Conceptually, CSR “preserves the recognition module while switching the effector module,” allowing the same antigen specificity to adopt distinct complement activation capacity, Fc receptor-binding profiles, in vivo distribution, and half-life across tissues and immune phases.

IV. Structural and Functional Features of Major Isotypes

4.1 IgM: Primary Responses and Potent Complement Activation

IgM is the predominant BCR form on naïve B cells and is typically the first secreted antibody produced during primary immune responses. Secreted IgM commonly exists as a pentamer linked by a J chain, conferring high valency:

① high avidity enables effective binding to multivalent antigens even when single-site affinity is moderate;

② it is among the most potent initiators of the classical complement pathway, enabling rapid amplification of humoral effector mechanisms early in infection;

③ serum IgM is an important indicator of recent infection or acute-phase responses.

4.2 IgG: The Dominant Serum Isotype and Multi-Pathway Effector Output

IgG is the most abundant serum isotype with the broadest distribution. It has a relatively long half-life (via FcRn-mediated recycling) and can cross the placenta, forming a key basis of passive immunity. IgG subclasses differ in structure and function:

① IgG1/IgG3: stronger complement activation and FcγR binding, often preferred when ADCC/CDC is required;

② IgG2: more suited to responses against polysaccharide antigens;

③ IgG4: generally weaker complement activation and may be associated with immune tolerance or immunomodulation in certain contexts.

Overall, IgG mediates neutralization, opsonization, ADCC, CDC, and immune complex clearance, and serves as the scaffold for most therapeutic monoclonal antibodies and intravenous immunoglobulin (IVIG).

4.3 IgA: The Core Antibody of Mucosal Barriers

IgA exists in serum and, as secretory IgA (sIgA), is abundant in mucosal secretions of the respiratory, gastrointestinal, and reproductive tracts. sIgA is typically dimeric and contains a J chain and secretory component, improving stability in protease-rich environments. Major functions of IgA include:

① blocking pathogen adhesion to epithelial cells to achieve “immune exclusion”;

② generally limited strong complement activation, supporting effective mucosal defense with lower inflammatory burden;

③ contributing to maintenance of microbiome homeostasis, particularly in the gut.

4.4 IgE: Allergic Responses and Anti-Helminth Immunity

IgE is present at very low concentrations in serum but binds with high affinity to FcεRI on mast cells and basophils. Upon re-exposure to the same antigen, antigen-mediated crosslinking of IgE triggers degranulation and release of inflammatory mediators, making IgE a key molecule in type I hypersensitivity. IgE also participates in immune clearance of helminths and other large parasites.

4.5 IgD: B Cell Maturation and Immune Homeostasis

IgD mainly exists as a membrane-bound form and, together with IgM, constitutes the BCR complex on mature naïve B cells, contributing to activation threshold setting and peripheral immune homeostasis. Soluble IgD in serum is low, and its functions remain under active investigation, though it has been implicated in certain mucosal responses and immunoregulation.

V. Fc-Mediated Effector Pathways: Fc Receptors, Complement, and FcRn

5.1 Fc Receptor Networks and Cellular Effector Functions

Different immunoglobulin isotypes engage their respective Fc receptors via Fc regions, thereby linking humoral responses to cellular effector modules. IgG interacts with the Fcγ receptor (FcγR) family to mediate activation or inhibition of macrophages, dendritic cells, neutrophils, and NK cells:

① activating Fc receptors (with ITAM motifs) promote phagocytosis, inflammatory cytokine release, and ADCC;

② inhibitory Fc receptors (with ITIM motifs) provide negative regulation to constrain excessive inflammation and immunopathology.

IgA signals through FcαR in mucosal-related pathways, while IgE engages FcεR to couple to allergic and anti-parasitic responses. Collectively, Fc receptor networks establish a dynamic balance between amplification and restraint.

5.2 The Classical Complement Pathway and Structural Dependence

When IgM and certain IgG subclasses form appropriate spatial arrangements on antigen surfaces, their Fc regions recruit C1q to initiate the classical complement pathway, leading to:

① C3b-mediated opsonization and immune complex clearance;

② formation of the C5b-9 membrane attack complex and lysis of target cells;

③ amplification of inflammation via anaphylatoxins such as C3a and C5a.

Complement activation efficiency depends not only on isotype/subclass but also on antigen density, antibody clustering state, hinge flexibility, and Fc glycosylation.

5.3 FcRn-Mediated Half-Life Control and Trans-Barrier Transport

In acidic endosomes, FcRn binds the IgG Fc region and rescues IgG from lysosomal degradation by recycling it back to the cell surface, where it is released under neutral pH—thereby extending IgG half-life. In the placenta and some mucosal barriers, FcRn also mediates IgG transcytosis, providing passive humoral protection to the fetus and newborn. In engineered antibodies, targeted mutations at the FcRn binding interface are commonly used to extend or shorten half-life, and FcRn antagonism strategies can be used to accelerate clearance of pathogenic IgG.

VI. Preparation and Analysis: From Plasma-Derived Products to Recombinant Antibodies

6.1 Plasma-Derived Immunoglobulin Products

Plasma-derived immunoglobulin preparations are produced from healthy donor plasma, typically via:

① cold ethanol fractionation to isolate IgG-enriched fractions;

② chromatographic steps (e.g., ion exchange and gel filtration) to remove impurities and polymers;

③ layered viral inactivation/removal processes (pasteurization, solvent/detergent treatment, nanofiltration) to minimize viral risk;

④ formulation into stabilizing buffers and finished as intravenous (IVIG) or subcutaneous (SCIG) products.

These preparations are predominantly polyclonal IgG and are used for immunoglobulin replacement and immunomodulatory therapy. Key quality control focuses include purity, aggregate content, potency stability, and viral safety.

6.2 Recombinant Engineered Antibodies and Derived Formats

Recombinant antibodies are primarily produced in mammalian expression systems (e.g., CHO cells) by obtaining antigen-specific VH/VL sequences, constructing expression vectors, selecting stable high-producing cell lines, scaling suspension culture, and purifying via Protein A/G affinity chromatography followed by multi-step polishing chromatography. Building on this foundation, additional engineering can include:

① humanization and affinity maturation to reduce immunogenicity and improve binding;

② Fc and glycoengineering to tune Fc receptor affinity, complement activation, half-life, and inflammatory phenotype;

③ format expansion to bispecific/multispecific antibodies, antibody–drug conjugates (ADCs), and antibody fragments (Fab, scFv, VHH), transforming immunoglobulins into programmable biologics platforms.

6.3 Critical Quality Attributes and Characterization Methods

In R&D and manufacturing, immunoglobulin products commonly emphasize the following critical quality attributes (CQAs):

① structural integrity and aggregation: evaluated by reducing/non-reducing SDS-PAGE, CE-SDS, and SEC-HPLC to quantify monomers, fragments, and aggregates;

② glycosylation and charge heterogeneity: analyzed by mass spectrometry, glycan profiling, isoelectric focusing, or ion-exchange chromatography;

③ functional activity: antigen-binding kinetics by ELISA and SPR/BLI, and effector function by ADCC, ADCP, CDC, and neutralization assays;

④ safety: sterility, endotoxin, and residual viral testing to ensure clinical safety.

VII. Clinical and Translational Applications

7.1 Immunoglobulin Replacement and Immunomodulation

For primary antibody deficiencies, certain secondary hypogammaglobulinemias, and patients with severe recurrent infections, IVIG or SCIG replacement therapy reduces the risk of serious infections by maintaining adequate IgG trough levels. In Kawasaki disease, selected autoimmune neurological disorders, and certain refractory autoimmune diseases, high-dose IVIG exerts immunomodulatory effects via multiple mechanisms, including Fc receptor blockade, clearance of complement fragments, anti-idiotypic network modulation, and glycoform-associated anti-inflammatory pathways.

7.2 Therapeutic Monoclonal Antibodies and Engineered Antibody Drugs

Therapeutic monoclonal antibodies and derived formats (bispecifics, ADCs, etc.) have become major treatment modalities for cancer, autoimmune diseases, and selected infectious diseases:

① receptor/ligand blockade antibodies that reshape signaling networks by inhibiting growth factors or immune checkpoint pathways;

② Fc-effector antibodies that directly eliminate target cells via ADCC/CDC and related mechanisms;

③ bispecific antibodies that simultaneously recognize tumor antigens and immune cell receptors to enable colocalization and immune cell recruitment;

④ ADCs that deliver cytotoxic payloads via antibody-mediated targeting to improve therapeutic window.

VIII. Aladdin-Related Products

Catalog No.	Product Name	Grade and Purity	Application Scenario	Handling Notes
np001055	Immunoglobulin M (IgM), Normal Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.18	IgM standard/positive control; studies on classical complement pathway and multivalent binding	Polymers are prone to aggregation; aliquot, minimize freeze–thaw cycles and vigorous mixing
np001056	Immunoglobulin M (IgM), Human Myeloma Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.18	Monoclonal-background IgM control; methodological consistency verification	Phenotype may differ from polyclonal IgM; specify source for quantitation/comparisons
np001053	Immunoglobulin M, mu Chain, Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.33	Chain-specific antibody validation; domain/epitope studies	Not equivalent to full-length IgM effector function; interpret quantitation as a fragment
np001054	Immunoglobulin M, Fc5mu, Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.18	Fc interaction studies; receptor/complement binding verification	Suitable for Fc-end binding verification; conformational differences vs full-length may affect binding strength
np001077	Immunoglobulin E (IgE), Normal Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.33	IgE quantification/calibration; FcεRI-related studies	Prone to adsorption; use low-binding consumables and include IgG negative controls
np001079	Immunoglobulin E (IgE), Human Myeloma Plasma, Kappa	≥95%(SDS-PAGE), Extinction Coefficient: 1.46	Monoclonal IgE control; κ light-chain assay validation	Parallel testing with λ helps exclude light-chain bias
np001078	Immunoglobulin E (IgE), Human Myeloma Plasma, Lambda	≥95%(SDS-PAGE), Extinction Coefficient: 1.46	Monoclonal IgE control; λ light-chain assay validation	Use alongside κ for cross-reactivity and isotype-bias assessment
np001080	Immunoglobulin D (IgD), Normal Human Plasma	ExactAb™, Validated, Carrier Free, ≥95%(SDS-PAGE), See COA	IgD research; assay development	Run IgM/IgG controls in parallel; first verify assay specificity
np001084	Immunoglobulin A (IgA), Normal Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient = 1.32	Serum IgA control; method validation	Different from sIgA; specify the molecular form for mucosal-related conclusions
np001083	Immunoglobulin A1 (IgA1), Human Myeloma Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.32	IgA1 subclass studies; subclass-specific assay validation	Test in parallel with IgA2 to assess cross-reactivity
np001082	Immunoglobulin A2 (IgA2), Human Myeloma Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.32	IgA2 subclass studies; subclass-specific assay validation	Test in parallel with IgA1 to distinguish subclass recognition
np001017	Secretory Immunoglobulin A (SigA) from Human Colostrum	BioReagent, ≥95%(SDS-PAGE), Pre-lyophilization Protein Concentration	Mucosal immunity models; sIgA barrier function studies	Contains J chain/secretory component; reconstitute and handle gently to avoid structural disruption
np001074	Immunoglobulin G (IgG), Normal Human Plasma	Carrier Free, ≥95%(SDS-PAGE), Extinction Coefficient: 1.36	General IgG control; FcRn/complement/receptor studies	Aggregates can bias FcγR readouts; assess by SEC when necessary
np001070	Immunoglobulin G, FC Fragment, Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.35	Fc-end binding verification; anti-Fc secondary antibody/receptor assays	Not for antigen-binding experiments; interpret with full-length IgG in parallel
np001071	Immunoglobulin G, Fab Fragment, Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.35	Fab-end studies; removal of Fc effector interference	No Fc effector functions; suitable as a “binding-only” control
np001057	Immunoglobulin G4 (IgG4), Normal Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.36	IgG4 subclass control; low-effector reference	Compare with IgG1/IgG3 to highlight effector differences
np001059	Immunoglobulin G3 (IgG3), Normal Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.36	High-effector subclass control; complement/receptor studies	Hinge differences may affect stability; assess integrity prior to functional assays
np001061	Immunoglobulin G2 (IgG2),  Human Myeloma Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.36	IgG2 subclass control; subclass-specific assay validation	Suitable for verifying anti-IgG2 specificity and cross-reactivity
np001062	Immunoglobulin G1 (IgG1), Normal Human Plasma	≥95%(SDS-PAGE), Extinction Coefficient: 1.36	IgG1 scaffold control; reference for engineered antibodies	Appropriate baseline for Fc/glycoengineering comparisons
np001063	Immunoglobulin G1 (IgG1), Human Myeloma Plasma, FC Fragment	≥95%(SDS-PAGE), Extinction Coefficient: 1.35	IgG1 Fc control; FcγR/FcRn/C1q binding verification	Focuses on Fc-end effects; interpret alongside full-length IgG1 for robustness
np001064	Immunoglobulin G1 (IgG1), Human Myeloma Plasma, Fab Fragment	≥95%(SDS-PAGE), Extinction Coefficient: 1.35	IgG1 Fab control; anti-Fab reagent verification	Removes Fc effects; adjust quantitation by fragment molecular weight
G304901	γ-Globulins from bovine blood	≥98%	Blocking/background diluent protein; bovine Ig-related controls	Polyclonal mixture; batch variation may affect background—fix batch when possible
Ab170213	Human IgG	Carrier Free, ExactAb™, Azide Free, Validated, ≥95%(SDS-PAGE), See COA	Reference IgG control; platform method validation	More suitable as “reagent/reference material”; record lot and verify specifications via COA
Ab180314	Human IgG (Biotin)	ExactAb™, Validated, See COA	SA-system capture/detection; ELISA/pulldown controls	Avoid interference from free biotin; verify labeling impact on function
Ab185027	Mouse IgG2a-Fc	Carrier Free, Recombinant, ExactAb™, Azide Free, Validated, ≥95%(SDS-PAGE), See COA	Fc-end control; anti-mouse Fc secondary antibody verification	Suitable for Fc receptor/anti-Fc recognition verification; not for antigen-binding readouts
Ab180318	Rabbit IgG (Biotin)	ExactAb™, Validated, 1.0 mg/mL	Biotinylated isotype/background control	Suitable as isotype/non-specific binding control; avoid interference from free biotin
Ab115835	Goat Anti-Mouse IgG H&L Antibody	Carrier Free, ExactAb™, Validated, See COA	Secondary antibody (WB/ELISA/IF/FC); detection of mouse primary antibodies	H+L recognition is broader; perform titration and include secondary-only controls
Ab138205	Goat Anti-Rabbit IgG H&L (AF488)	ExactAb™, High Performance, Validated, Ex:490nm, Em:525nm, 1 mg/mL	Fluorescent secondary (IF/FC); detection of rabbit primary antibodies	Protect from light; run compensation and single-stain controls in multicolor assays
Ab170144	Goat Anti-Rabbit IgG H&L (HRP)	ExactAb™, Azide Free, Validated, High Performance, Pre-adsorbed, 1.0 mg/mL	HRP secondary (WB/ELISA); detection of rabbit primary antibodies	Sodium azide inhibits HRP; pre-adsorption helps reduce cross-reactivity
Ab136882	Donkey Anti-Rabbit IgG H&L (AF647)	ExactAb™, Validated, Azide Free, Ex:650nm, Em:668nm, 2.0mg/ml	Far-red fluorescent secondary (IF/FC); detection of rabbit primary antibodies	Protect from light; titrate high-concentration reagents to optimize S/N
Ab181963	Goat Anti-Human IgG (AF647)	ExactAb™, Validated, Ex:650nm, Em:668nm, 1.0 mg/mL	Human IgG fluorescent secondary (IF/FC)	Protect from light and perform compensation; verify recognition scope (total IgG vs region-specific) before quantitation
Ab216757	Goat Anti-Human IgG Fc (AF700)	ExactAb™, Validated, 1.0 mg/mL	Fc-specific fluorescent secondary; distinguishes full-length IgG from Fab	Fc-specificity supports fragment discrimination; ensure instrument compatibility and compensation for AF700 channel
Ab181952	Goat Anti-Mouse IgG H&L (AF647)	Validated, Ex:650nm, Em:668nm, 1.0 mg/mL	AF647 fluorescent secondary (IF/FC); detection of mouse primary antibodies	Protect from light; run single-stain, FMO, and isotype controls
Ab220016	Goat Anti-Mouse IgG H&L (AF594) (Ready to use)	ExactAb™, Validated, See COA	Ready-to-use fluorescent secondary (imaging/flow); detection of mouse primary antibodies	Ready-to-use format improves standardization; protect from light and include secondary-only controls
Ab220072	Goat Anti-Rabbit IgG H&L (AF660) (Ready to use)	ExactAb™, Validated, See COA	Ready-to-use far-red fluorescent secondary; detection of rabbit primary antibodies	Ready-to-use format improves consistency; protect from light and control for spectral spillover/compensation
Ab176439	Rabbit Anti-Mouse IgG (Biotin)	ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL	Biotinylated secondary; SA amplification systems (WB/ELISA/IF)	Control endogenous/free biotin background; titrate to define linear range
Ab176120	Goat Anti-Bovine IgG H&L Antibody	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA	Bovine IgG detection secondary; serology/immunoassays	Verify cross-reactivity with other species; pair with bovine Ig standards for quantitation
Ab175834	Goat Anti-Human IgG (FITC)	ExactAb™, Validated, Azide Free, Ex:498nm, Em:517nm, 1.0 mg/mL	FITC fluorescent secondary (IF/FC); human IgG detection	FITC is prone to photobleaching; protect from light and run compensation in multicolor panels

Immunoglobulins integrate highly modular architectures to couple the diversity-generating mechanisms of V(D)J recombination, somatic hypermutation, and class-switch recombination with Fc receptor networks, the complement system, and FcRn-governed in vivo behaviors, forming the molecular foundation of adaptive humoral immunity. Technologically, immunoglobulins have evolved from “natural defense molecules” into engineerable biologics platforms—from plasma-derived products to recombinant engineered antibodies and onward to emerging formats such as bispecific antibodies and ADCs. Looking ahead, continued innovation in Fc engineering, glycoengineering, multispecific formats, and novel expression and purification processes will further expand the clinical and translational landscape across oncology, infectious diseases, autoimmunity, and precision medicine. In parallel, scalable manufacturing and robust quality control systems will remain decisive determinants of real-world accessibility and long-term clinical value.

Aladdin: https://www.aladdinsci.com/